Role of U.S. military research programs in the development of U.S.-licensed vaccines for naturally occurring infectious diseases

Vaccine

Volumn 25, Issue 41, 2007, Pages 7017-7030

  Kitchen, Lynn W ^a   Vaughn, David W ^a  

^a U S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND   (United States)

Author keywords

U.S. FDA; U.S. military; Vaccines

Indexed keywords

ADENOVIRUS 4 VACCINE; ADENOVIRUS 7 VACCINE; AZITHROMYCIN; BACTERIAL VACCINE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; DENGUE VACCINE; DEXAMETHASONE; ESCHERICHIA COLI VACCINE; HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; HEPATITIS E VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN; INFLUENZA VACCINE; JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; MALARIA VACCINE; MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; RUBELLA VACCINE; SHIGELLA VACCINE; TYPHOID VACCINE; TYPHUS VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VIRUS VACCINE;

ADENOVIRUS; ADENOVIRUS 7; ARM DISEASE; ARMY; CAMPYLOBACTER; CLINICAL TRIAL; CRUSH SYNDROME; DENGUE; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESEARCH; DRUG SAFETY; ENTEROBACTER INFECTION; EPIDEMIC ENCEPHALITIS; ESCHERICHIA COLI; FOOD AND DRUG ADMINISTRATION; GRAM NEGATIVE INFECTION; HEMORRHAGIC FEVER; HEPATITIS A; HEPATITIS B; HEPATITIS E; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INFECTION CONTROL; INFECTIOUS DIARRHEA; INFLUENZA; LICENCE; MALARIA; MENINGOCOCCOSIS; MILITARY RESEARCH; NONHUMAN; PASSIVE IMMUNIZATION; POLIOMYELITIS; PRIORITY JOURNAL; RESPIRATORY DISTRESS; REVIEW; RUBELLA; SCRUB TYPHUS; SHIGELLA; SWELLING; TYPHOID FEVER; UNITED STATES; VACCINE PRODUCTION; VIRUS INFECTION; VIRUS TRANSMISSION;

BIOMEDICAL RESEARCH; COMMUNICABLE DISEASE CONTROL; DRUG APPROVAL; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MILITARY PERSONNEL; VACCINES;

EID: 34748834159     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.07.030     Document Type: Review

References (117)

1. Pittman M. The regulation of biologic products, 1902-1972. In: Greenwald H.R., and Harden V.A. (Eds). National Institute of Allergy and Infectious Diseases: intramural contributions, 1887-1987 (1987), National Institute of Allergy and Infectious Diseases, Bethesda, MD 61-70. http://www.history.nih.gov/articles/NIAID_Intramural_Contributions.pdf (accessed April 8, 2007)
2. Center for Biologics Evaluation and Research. Science and the regulation of biological products: from a rich history to a challenging future (2002), Food and Drug Administration, Rockville, MD. http://www.fda.gov/cber/inside/cberbkp2.pdf, http://www.fda.gov/cber/inside/cberbkp2.pdf, and http://www.fda.gov/cber/inside/cberbkp3.pdf (accessed April 8, 2007)
3. Barry J.M. The great influenza: the epic story of the deadliest plague in history (2004), Viking, New York
4. Crosby A.W. Epidemic and peace, 1918 (1976), Greenwood Press, Westport, CT
5. In: Woodward T.E. (Ed). The Armed Forces Epidemiological Board: the histories of the commissions (1994), Office of the Surgeon General, Department of the Army, Washington, DC. http://history.amedd.army.mil/booksdocs/historiesofcomsn/default.htm (accessed September 28, 2006)
6. Francis Jr. T., Salk J.E., Pearson H.E., and Brown P.N. Protective effect of vaccination against induced influenza A. J Clin Invest 24 4 (1945) 536-546
7. Salk J.E., Pearson H.E., Brown P.N., and Francis Jr. T. Protective effect of vaccination against induced influenza B. J Clin Invest 24 4 (1945) 547-553
8. Salk J.E., Menke Jr. W.J., and Francis Jr. T. A clinical, epidemiological and immunological evaluation of vaccination against epidemic influenza. Am J Epidemiol 42 1 (1945) 57-93
9. Francis Jr. T. Vaccination against influenza. Bull World Health Organ 8 5-6 (1953) 725-741
10. McNinch J.H., and Mason R.P. The role of military medical services in future epidemic influenza. Am Rev Respir Dis 83 2 (1961) 198-200
11. Gaydos J.C., Hodder R.A., Top Jr. F.H., Soden V.J., Allen R.G., Bartley J.D., et al. Swine influenza A at Fort Dix, New Jersey (January-February 1976). I. Case finding and clinical study of cases. J Infect Dis 136 Suppl (1977) S356-S362
12. Gaydos J.C., Hodder R.A., Top Jr. F.H., Allen R.G., Soden V.J., Nowosiwsky T., et al. Swine influenza A at Fort Dix, New Jersey (January-February 1976). II. Transmission and morbidity in units with cases. J Infect Dis 136 Suppl (1977) S363-S368
13. Hodder R.A., Gaydos J.C., Allen R.G., Top Jr. F.H., Nowosiwsky T., and Russell P.K. Swine influenza A at Fort Dix, New Jersey (January-February 1976). III. Extent of spread and duration of the outbreak. J Infect Dis 136 Suppl (1977) S369-S375
14. Schonberger L.B., Bregman D.J., Sullivan-Bolyai J.Z., Keenlyside R.A., Ziegler D.W., Retailliau H.F., et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 110 2 (1979) 105-123
15. Roscelli J.D., Bass J.W., and Pang L. Guillain-Barre syndrome and influenza vaccination in the US Army, 1980-1988. Am J Epidemiol 133 9 (1991) 952-955
16. Kaplan J.E., Katona P., Hurwitz E.S., and Schonberger L.B. Guillain-Barre syndrome in the United States, 1979-1980 and 1980-1981. Lack of an association with influenza vaccination. JAMA 248 6 (1982) 698-700
17. Ottolini M.G., and Burnett M.W. History of U.S. military contributions to the study of respiratory infections. Mil Med 170 4 Suppl (2005) 66-70
18. Meiklejohn G., Zajac R.A., and Evans M.E. Influenza at Lowry Air Force Base in Denver, 1982-1986. J Infect Dis 156 4 (1987) 649-651
19. Meiklejohn G. Viral respiratory disease at Lowry Air Force Base in Denver, 1952-1982. J Infect Dis 148 5 (1983) 775-784
20. Meiklejohn G., Eickhoff T.C., Graves P., and I J. Antigenic drift and efficacy of influenza virus vaccines, 1976-1977. J Infect Dis 138 5 (1978) 618-624
21. Meiklejohn G., Eickhoff T.C., and Graves P. Antibody response of young adults to experimental influenza A/New Jersey/76 virus vaccines. J Infect Dis 136 Suppl (1977) S456-S459
22. Hoke Jr. C.H., Hopkins J.A., Meiklejohn G., and Mostow S.R. Comparison of several wild-type influenza viruses in the ferret tracheal organ culture system. Rev Infect Dis 1 6 (1979) 946-954
23. Gremillion D.H., Meiklejohn G., Graves P., and I J. Efficacy of single-dose influenza in Air Force recruits. J Infect Dis 147 6 (1983) 1099
24. Hirsch M.S. Measles, mumps, rubella, parvovirus, and poxvirus. ACP medicine (2006), WebMD, New York
25. Grabenstein J.D. ImmunoFacts: vaccines and immunologic drugs (2005), Wolters Kluwer Health, Inc., St. Louis, MO
26. Artenstein A.W., Opal J.M., Opal S.M., Tramont E.C., Peter G., and Russell P.K. History of U.S. military contributions to the study of vaccines against infectious diseases. Mil Med 170 4 Suppl (2005) 3-11
27. Centers for Disease Control and Prevention. Elimination of rubella and congenital rubella syndrome, United States, 1969-2004. MMWR 54 11 (2005) 279-282
28. Sivan A., Lee T., Binn L., and Gaydos J. Where's adeno? A search for the occurrence of adenovirus-associated respiratory disease outside of the U.S. military. Presented at the International Conference on Emerging Infectious Diseases (2006)
29. Hilleman M.R., and Werner J.H. Recovery of new agent from patients with acute respiratory illness. Proc Soc Exp Biol Med 85 1 (1954) 183-188
30. Hilleman M.R., Werner J.H., Dascomb H.E., Butler R.L., and Stewart M.T. Epidemiology of RI(RI-67) group respiratory virus infections in recruit populations. Am J Hyg 62 1 (1955) 29-42
31. Anonymous. Appraisal of studies in the light of subsequent knowledge of etiology of the acute viral respiratory diseases. Am Rev Respir Dis 97 6 Pt 2 (1968) 34-65
32. Dingle J.H., and Langmuir A.D. Epidemiology of acute, respiratory disease in military recruits. Am Rev Respir Dis 97 6 Suppl (1968) 1-65
33. Gaydos C.A., and Gaydos J.C. Adenovirus vaccines. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. 4th ed. (2004), Saunders, Philadelphia 863-885
34. Chanock R.M., Ludwig W., Heubner R.J., Cate T.R., and Chu L.W. Immunization by selective infections with type 4 adenovirus grown in human diploid tissue cultures. I. Safety and lack of oncogenicity and tests for potency in volunteers. JAMA 195 6 (1966) 445-452
35. Edmondson W.P., Purcell R.H., Gundelfinger B.F., Love J.W., Ludwig W., and Chanock R.M. Immunization by selective infection with type 4 adenovirus grown in human diploid tissue culture. II. Specific protective effect against epidemic disease. JAMA 195 6 (1966) 453-459
36. Top Jr. F.H., Grossman R.A., Bartelloni P.J., Segal H.E., Dudding B.A., Russell P.K., et al. Immunization with live types 7 and 4 adenovirus vaccines. I. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccines in humans. J Infect Dis 124 2 (1971) 148-154
37. Top Jr. F.H., Buescher E.L., Bancroft W.H., and Russell P.K. Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. J Infect Dis 124 2 (1971) 155-160
38. Gray G.C., Callahan J.D., Hawksworth A.W., Fisher C.A., and Gaydos J.C. Respiratory diseases among U.S. military personnel: countering emerging threats. Emerg Infect Dis 5 3 (1999) 379-385
39. Gray G.C., Goswami P.R., Malasig M.D., Hawksworth A.W., Trump D.H., Ryan M.A., et al. Adult adenovirus infections: loss of orphaned vaccines precipitates military respiratory disease epidemics. Clin Infect Dis 31 3 (2000) 663-670
40. Marrazzo J.M. Infections due to Neisseria. ACP Medicine (2006), WebMD, New York
41. Alexander C.E., Sanborn W.R., Cherriere G., Crocker Jr. W.H., Ewald P.E., and Kay C.R. Sulfadiazine-resistant group A Neisseria meningitidis. Science 161 845 (1968) 1019
42. Goldschneider I., Gotschlich E.C., and Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 129 6 (1969) 1307-1326
43. Goldschneider I., Gotschlich E.C., and Artenstein M.S. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med 129 6 (1969) 1327-1348
44. Gotschlich E.C., Liu T.Y., and Artenstein M.S. Human immunity to the meningococcus. III. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides. J Exp Med 129 6 (1969) 1349-1365
45. Gotschlich E.C., Goldschneider I., and Artenstein M.S. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med 129 6 (1969) 1367-1384
46. Gotschlich E.C., Goldschneider I., and Artenstein M.S. Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. J Exp Med 129 6 (1969) 1385-1395
47. Artenstein M.S., Gold R., Zimmerly J.G., Wyle F.A., Schneider H., and Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med 282 8 (1970) 417-420
48. Gold R., and Artenstein M.S. Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-1970. Bull World Health Organ 45 3 (1971) 279-282
49. Griffiss J.M., Brandt B.L., Altieri P.L., Pier G.B., and Berman S.L. Safety and immunogenicity of group Y and group W135 meningococcal capsular polysaccharide vaccines in adults. Infect Immun 34 3 (1981) 725-732
50. Griffiss J.M., Brandt B.L., and Broud D.D. Human immune response to various doses of group Y and W135 meningococcal polysaccharide vaccines. Infect Immun 37 1 (1982) 205-208
51. Armand J., Arminjon F., Mynard M.C., and Lafaix C. Tetravalent meningococcal polysaccharide vaccine groups A, C, Y, W 135: clinical and serological evaluation. J Biol Stand 10 4 (1982) 335-339
52. Hankins W.A., Gwaltney Jr. J.M., Hendley J.O., Farquhar J.D., and Samuelson J.S. Clinical and serological evaluation of a meningococcal polysaccharide vaccine groups A, C, Y, and W135. Proc Soc Exp Biol Med 169 1 (1982) 54-57
53. Brundage J.F., Ryan M.A., Feighner B.H., and Erdtmann F.J. Meningococcal disease among United States military service members in relation to routine uses of vaccines with different serogroup-specific components, 1964-1998. Clin Infect Dis 35 11 (2002) 1376-1381
54. Brundage J.F., and Zollinger W.D. Evolution of meningococcal disease epidemiology in the U.S. Army. In: Vedros N.A. (Ed). Evolution of meningococcal disease vol. 1 (1987), CRC Press, Boca Raton 5-25
55. U.S. Food and Drug Administration. Meningococcal polysaccharide (serogroups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (Menactra) [product approval information, licensing action]. Available at: http://www.fda.gov/cber/products/mpdtave011405.htm (accessed October 6, 2006).
56. Leake J.A.D., and Perkins B.A. Meningococcal disease: challenges in prevention and management. Infect Med 17 5 (2000) 364-377
57. Boslego J., Garcia J., Cruz C., Zollinger W., Brandt B., Ruiz S., et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine 13 9 (1995) 821-829
58. Drabick J.J., Brandt B.L., Moran E.E., Saunders N.B., Shoemaker D.R., and Zollinger W.D. Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers. Vaccine 18 1-2 (1999) 160-172
59. Fisseha M., Chen P., Brandt B., Kijek T., Moran E., and Zollinger W. Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination. Infect Immun 73 7 (2005) 4070-4080
60. Sawyer W.A., Meyer K.F., Eaton M.D., Bauer J.H., Putnam P., and Schwentker F.F. Jaundice in Army personnel in the western region of the United States and its relation to vaccination against yellow fever. Part I. Am J Epidemiol 39 3 (1944) 337-430
61. Sawyer W.A., Meyer K.F., Eaton M.D., Bauer J.H., Putnam P., and Schwentker F.F. Jaundice in Army personnel in the western region of the United States and its relation to vaccination against yellow fever. Parts II-IV. Am J Epidemiol 40 1 (1944) 35-107
62. Findlay G.M., and Martin N.H. Jaundice following yellow fever immunisation: transmission by intranasal instillation. Lancet 1 244 (1943) 678-680
63. Hargett M.V., Burruss H.W., and Donovan A. Aqueous-base yellow fever vaccine. Pub Health Rep 58 (1943) 505-512
64. Blumberg B.S. Hepatitis B: the hunt for a killer virus (2002), Princeton University Press, Princeton
65. Dooley D.P. History of U.S. military contributions to the study of viral hepatitis. Mil Med 170 4 Suppl (2005) 71-76
66. Szmuness W., Stevens C.E., Zang E.A., Harley E.J., and Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology 1 5 (1981) 377-385
67. Bancroft W.H., Mundon F.K., and Russell P.K. Detection of additional antigenic determinants of hepatitis B antigen. J Immunol 109 4 (1972) 842-848
68. Bancroft W.H., Snitbhan R., Scott R.M., Tingpalapong M., Watson W.T., Tanticharoenyos P., et al. Transmission of hepatitis B virus to gibbons by exposure to human saliva containing hepatitis B surface antigen. J Infect Dis 135 1 (1977) 79-85
69. Cirillo V.J. Bullets and Bacilli: the Spanish-American War and military medicine (2004), Rutgers University Press, New Brunswick, NJ
70. Bollet A.J. Civil war medicine: challenges and triumphs (2002), Galen Press, Tucson p. 257-81
71. Russell F.F. Antityphoid inoculation. Am J Med Sci 146 (1913) 803-833
72. Hardy A. "Straight back to barbarism": antityphoid inoculation and the Great War, 1914. Bull Hist Med 74 2 (2000) 265-290
73. U.S. Army Surgeon General's Office. The Medical Department of the United States Army in the World War, vol. IX: communicable and other diseases (1928), U.S. Government Printing Office, Washington, DC p. 15-60
74. U.S. Army Medical School. Immunization to typhoid fever: results obtained in the prevention of typhoid fever in the United States Army, United States Navy, and Civilian Conservation Corps, by the use of vaccines (1941), Johns Hopkins Press, Baltimore
75. Levine M.M., Ferreccio C., Black R.E., and Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1 8541 (1987) 1049-1052
76. Black R.E., Levine M.M., Ferreccio C., Clements M.L., Lanata C., Rooney J., et al. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Vaccine 8 1 (1990) 81-84
77. Ferreccio C., Levine M.M., Rodriguez H., and Contreras R. Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J Infect Dis 159 4 (1989) 766-769
78. Simanjuntak C.H., Paleologo F.P., Punjabi N.H., Darmowigoto R., Soeprawoto, Totosudirjo H., et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 338 8774 (1991) 1055-1059
79. Woodward T.E., Smadel J.E., Ley Jr. H.L., Green R., and Mankikar D.S. Preliminary report on the beneficial effect of chloromycetin in the treatment of typhoid fever. Ann Intern Med 29 (1948) 131-134
80. Tribble D., Girgis N., Habib N., and Butler T. Efficacy of azithromycin for typhoid fever. Clin Infect Dis 21 4 (1995) 1045-1046
81. Wallace M.R., Yousif A.A., Mahroos G.A., Mapes T., Threlfall E.J., Rowe B., et al. Ciprofloxacin versus ceftriaxone in the treatment of multiresistant typhoid fever. Eur J Clin Microbiol Infect Dis 12 12 (1993) 907-910
82. Frenck Jr. R.W., Nakhla I., Sultan Y., Bassily S.B., Girgis Y.F., David J., et al. Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children. Clin Infect Dis 31 5 (2000) 1134-1138
83. Girgis N.I., Butler T., Frenck R.W., Sultan Y., Brown F.M., Tribble D., et al. Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance. Antimicrob Agents Chemother 43 6 (1999) 1441-1444
84. Hoffman S.L., Punjabi N.H., Kumala S., Moechtar M.A., Pulungsih S.P., Rivai A.R., et al. Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone. N Engl J Med 310 2 (1984) 82-88
85. Lim M.L., Murphy G.S., Calloway M., and Tribble D. History of U.S. military contributions to the study of diarrheal diseases. Mil Med 170 4 Suppl (2005) 30-38
86. Vaughn D.W., and Hoke Jr. C.H. The epidemiology of Japanese encephalitis: prospects for prevention. Epidemiol Rev 14 (1992) 197-221
87. Buescher E.L., and Scherer W.F. The ecology of Japanese encephalitis virus in Japan. Proceedings of the sixth international congresses on tropical medicine and malaria, vol. V. An Inst Med Trop (Lisb) 16 Suppl 9 (1959) 126-131
88. Defraites R.F., Gambel J.M., Hoke Jr. C.H., Sanchez J.L., Withers B.G., Karabatsos N., et al. Japanese encephalitis vaccine (inactivated, BIKEN) in U.S. soldiers: immunogenicity and safety of vaccine administered in two dosing regimens. Am J Trop Med Hyg 61 2 (1999) 288-293
89. Hoke Jr. C.H. History of U.S. military contributions to the study of viral encephalitis. Mil Med 170 4 Suppl (2005) 92-105
90. Hoke C.H., Nisalak A., Sangawhipa N., Jatanasen S., Laorakapongse T., Innis B.L., et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 319 10 (1988) 608-614
91. Sanchez J.L., Hoke C.H., McCown J., DeFraites R.F., Takafuji E.T., Diniega B.M., et al. Further experience with Japanese encephalitis vaccine. Lancet 335 8695 (1990) 972-973
92. Burke D.S., and Nisalak A. Detection of Japanese encephalitis virus immunoglobulin M antibodies in serum by antibody capture radioimmunoassay. J Clin Microbiol 15 3 (1982) 353-361
93. Gambel J.M., DeFraites R., Hoke Jr. C., Brown A., Sanchez J., Karabatsos N., et al. Japanese encephalitis vaccine: persistence of antibody up to 3 years after a three-dose primary series. J Infect Dis 171 4 (1995) 1074
94. Bollet A.J. Civil war medicine: challenges and triumphs (2002), Galen Press, Tucson p. 283-306
95. Gellis S.S., Stokes Jr. J., Brother G.M., Hall W.H., Gilmore H.R., Beyer E., et al. The use of human immune serum globulin (gamma globulin) in infectious (epidemic) hepatitis in the Mediterranean theater of operations. I. Studies on prophylaxis in two epidemics of infectious hepatitis. JAMA 128 (1945) 1062-1063
96. Anonymous. Prophylactic gamma globulin for prevention of endemic hepatitis. Effects of US gamma globulin upon the incidence of viral hepatitis and other infectious diseases in US soldiers abroad. Arch Intern Med 128 5 (1971) 723-738
97. Conrad M.E., and Lemon S.M. Prevention of endemic icteric viral hepatitis by administration of immune serum gamma globulin. J Infect Dis 156 1 (1987) 56-63
98. Binn L.N., Bancroft W.H., Lemon S.M., Marchwicki R.H., LeDuc J.W., Trahan C.J., et al. Preparation of a prototype inactivated hepatitis A virus vaccine from infected cell cultures. J Infect Dis 153 4 (1986) 749-756
99. Sjogren M.H., Hoke C.H., Binn L.N., Eckels K.H., Dubois D.R., Lyde L., et al. Immunogenicity of an inactivated hepatitis A vaccine. Ann Intern Med 114 6 (1991) 470-471
100. Hoke Jr. C.H., Binn L.N., Egan J.E., DeFraites R.F., MacArthy P.O., Innis B.L., et al. Hepatitis A in the US Army: epidemiology and vaccine development. Vaccine 10 Suppl 1 (1992) S75-S79
101. Shrestha M.P., Mrigendra P., and Scott R.M. Protection against hepatitis E by a recombinant vaccine. Presented at the American Society of Tropical Medicine and Hygiene 54th annual meeting (2005)
102. Harden V.A. Rocky mountain spotted fever: history of a twentieth-century disease (1990), The Johns Hopkins University Press, Baltimore p. 175-96
103. Medical Department, U.S. Army. Preventive medicine in World War II, vol. III: personal health measures and immunization (1955), Office of the Surgeon General, Department of the Army, Washington, DC p. 319-23
104. Chattopadhyay S., Jiang J., Chan T.C., Manetz T.S., Chao C.C., Ching W.M., et al. Scrub typhus vaccine candidate Kp r56 induces humoral and cellular immune responses in cynomolgus monkeys. Infect Immun 73 8 (2005) 5039-5047
105. Sabin Vaccine Institute. Human Hookworm Vaccine Initiative (HHVI) overview. Available at: http://www.sabin.org/hookworm.htm (accessed October 11, 2006).
106. Bwire R. Bugs in armor: a tale of malaria and soldiering (1999), iUniverse.com, Inc, San Jose
107. Malaria outbreak among members of JTF Liberia: consensus conference report [October 9, 2003]. Available at: http://www-nehc.med.navy.mil/downloads/prevmed/JTFMalaria.pdf (accessed October 11, 2006).
108. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Aide P., et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366 9502 (2005) 2012-2018
109. Heppner Jr. D.G., Kester K.E., Ockenhouse C.F., Tornieporth N., Ofori O., Lyon J.A., et al. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 23 17-8 (2005) 2243-2250
110. Ballou W.R. Malaria vaccines in development. Expert Opin Emerg Drugs 10 3 (2005) 489-503
111. Gubler D.J. Commentary: Ashburn PM, Craig CF. Experimental investigations regarding the etiology of dengue [J Infect Dis 1907;4:440-75]. J Infect Dis 189 9 (2004) 1744-1783. http://www.journals.uchicago.edu/JID/journal/issues/v189n9/32484/32484.w eb.pdf (accessed April 28, 2007)
112. Sun W., Nisalak A., Gettayacamin M., Eckels K.H., Putnak J.R., Vaughn D.W., et al. Protection of rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination. J Infect Dis 193 12 (2006) 1658-1665
113. Sanders J.W., Putnam S.D., Riddle M.S., and Tribble D.R. Military importance of diarrhea: lessons from the Middle East. Curr Opin Gastroenterol 21 1 (2005) 9-14
114. Hooper J.W., Custer D.M., Thompson E., and Schmaljohn C.S. DNA vaccination with the Hantaan virus M gene protects hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in rhesus monkeys. J Virol 75 18 (2001) 8469-8477
115. Nitayaphan S., Pitisuttithum P., Karnasuta C., Eamsila C., de Souza M., Morgan P., et al. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis 190 4 (2004) 702-706
116. Duerr A., Wasserheit J.N., and Corey L. HIV vaccines: new frontiers in vaccine development. Clin Infect Dis 43 4 (2006) 500-511
117. Kitchen L.W., Vaughn D.W., and Skillman D.R. Role of US military research programs in the development of US Food and Drug Administration-approved antimalarial drugs. Clin Infect Dis 43 1 (2006) 67-71